A passionate kiss, then run: exocytosis and recycling of IgG by FcRn.
about
Neonatal Fc receptor mediates internalization of Fc in transfected human endothelial cellsFc-fusion technology and recombinant FVIII and FIX in the management of the hemophiliasDefining the immunological phenotype of Fc receptor-like B (FCRLB) deficient mice: Confounding role of the inhibitory FcγRIIbModern Technologies for Creating Synthetic Antibodies for Clinical application.Intracellular neutralization of shiga toxin 2 by an a subunit-specific human monoclonal antibody.Safety and prolonged activity of recombinant factor VIII Fc fusion protein in hemophilia A patients.Endocytosis at the blood-brain barrier: from basic understanding to drug delivery strategies.The role of Fc receptors in HIV infection and vaccine efficacy.Immunoglobulin responses at the mucosal interface.On the perplexingly low rate of transport of IgG2 across the human placenta.Non-fucosylated therapeutic antibodies as next-generation therapeutic antibodies.Vaccination against Chlamydia genital infection utilizing the murine C. muridarum model.Comparing different dosing regimens of bevacizumab in the treatment of neovascular macular degeneration: study protocol for a randomised controlled trialβ2-microglobulin is required for the full expression of xenobiotic-induced systemic autoimmunity.Recombinant factor IX-Fc fusion protein (rFIXFc) demonstrates safety and prolonged activity in a phase 1/2a study in hemophilia B patients.Improved systemic pharmacokinetics, biodistribution, and antitumor activity of CpG oligodeoxynucleotides complexed to endogenous antibodies in vivo.The chicken yolk sac IgY receptor, a mammalian mannose receptor family member, transcytoses IgY across polarized epithelial cells.The reproductive cycle is a pathogenic determinant during gonococcal pelvic inflammatory disease in mice.Field Guide to Challenges and Opportunities in Antibody-Drug Conjugates for Chemists.Pharmacokinetic properties of IgG and various Fc fusion proteins in mice.Deglycosylated anti-Abeta antibody dose-response effects on pathology and memory in APP transgenic mice.Improving effector functions of antibodies for cancer treatment: Enhancing ADCC and CDCImmune and non-immune functions of the (not so) neonatal Fc receptor, FcRn.Current options and new developments in the treatment of haemophilia.Development of long-acting recombinant FVIII and FIX Fc fusion proteins for the management of hemophilia.Role of enhanced half-life factor VIII and IX in the treatment of haemophilia.The multiple facets of FcRn in immunity.Antibody-drug conjugates: recent advances in conjugation and linker chemistries.Anti-Sp17 monoclonal antibody with antibody-dependent cell-mediated cytotoxicity and complement-dependent cytotoxicity activities against human ovarian cancer cells.Competition for FcRn-mediated transport gives rise to short half-life of human IgG3 and offers therapeutic potential.N-glycosylation as novel strategy to improve pharmacokinetic properties of bispecific single-chain diabodies.Regulation of the Human Fc-Neonatal Receptor alpha-Chain Gene FCGRT by MicroRNA-3181.Endosomal trafficking regulates receptor-mediated transcytosis of antibodies across the blood brain barrier.The antibody drug absorption following subcutaneous or intramuscular administration and its mathematical description by coupling physiologically based absorption process with the conventional compartment pharmacokinetic model.Maternal-Foetal Diabetes Modifies Neonatal Fc Receptor Expression on Human Leucocytes.Reduced elimination of IgG antibodies by engineering the variable region.
P2860
Q24651849-397AE930-E224-412C-B76B-FB88E6C208C1Q27014771-9B219F25-E1FD-42DF-9E12-0722C97A0CB6Q28512262-AB837435-8D4B-4BE2-AB1E-81150B74D2A6Q30467308-6E80A349-FE98-46D5-ABC3-A706226498F2Q30481790-B670688A-CDF2-4F58-92CF-A38412B21080Q30539596-AE0CD340-3774-4F4B-AB57-137E1B5711F1Q33996836-107752F7-2012-496C-8500-42CF6644666FQ33997395-2F1A2E0F-FA2B-419F-900A-699DB5D406EBQ34025272-4790CA0A-0D1B-4BF8-970C-C8AFCB087940Q34253508-A28F0E8B-1ED3-4466-B346-4F234AF9923EQ34574834-2558AFAB-3A32-4E64-88D7-314FC310BF52Q34739969-CC5FE272-7506-47CE-99F8-685B99A12A73Q35224191-E10B9D41-CA1F-4877-898B-6F40BB0824DCQ35671513-2A1D2FAE-E465-488C-9CB5-AF1E375401E1Q35692016-E5789B49-F3CF-4E52-854C-DD6F632ABEA0Q35990439-86563447-9C5F-4225-9433-162DE60E5D51Q36536590-1E154A5E-8A26-4B39-93A1-B030B235B74EQ37026470-061CC2C9-AC05-40E5-81C6-295501607182Q37066113-77C74D11-3AB0-44B1-8C22-62DAE083CD90Q37138252-043B5F99-8FA6-417B-880C-4CC827D034DCQ37353658-D1D34CA1-28D6-4B30-95D9-75586A6B88E9Q37403194-A614AEFB-4063-4FCE-8813-EA8377CB369CQ37502056-66BB3E9A-944A-4172-AEEC-3A037665A3C9Q37841547-0C6FA801-9717-4957-B526-FB7E17458313Q38127745-6F3F6BCB-BD5E-4F2E-B790-7152A0D7B88AQ38371071-EDE75E2F-E3E8-4F5D-8807-AB9EC0799D46Q38615385-1756196F-3DB2-4C82-AD34-83D6C818C4E3Q38981429-465661F9-6209-4008-94D5-1573F46A571DQ39422339-090CEF7C-F48C-4D4A-8EE7-AB5E3FA59856Q39424805-5166263B-D6CE-4FBB-B8B5-3D8CD13DDD75Q40021987-30E953F6-8AA4-46AD-8097-6FB194D50FF4Q47207165-2E63CF11-B81E-4401-BCEE-9D02CC815B7AQ47968587-BE3DA722-F0AC-43AA-8E75-94149B824BF1Q51253905-487735F0-0100-4F1C-9A22-5FF1FEADFBF0Q51609563-ED3B2B62-14E3-4DB5-BC96-871AB296311CQ51774820-FFE21D7F-A4AA-4D8E-8929-5248A906DA37
P2860
A passionate kiss, then run: exocytosis and recycling of IgG by FcRn.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
A passionate kiss, then run: exocytosis and recycling of IgG by FcRn.
@ast
A passionate kiss, then run: exocytosis and recycling of IgG by FcRn.
@en
type
label
A passionate kiss, then run: exocytosis and recycling of IgG by FcRn.
@ast
A passionate kiss, then run: exocytosis and recycling of IgG by FcRn.
@en
prefLabel
A passionate kiss, then run: exocytosis and recycling of IgG by FcRn.
@ast
A passionate kiss, then run: exocytosis and recycling of IgG by FcRn.
@en
P1476
A passionate kiss, then run: exocytosis and recycling of IgG by FcRn
@en
P2093
Richard S Blumberg
P356
10.1016/J.TCB.2004.11.004
P577
2005-01-01T00:00:00Z